Top

Irish Journal of Medical Science (1971 -)

Published in:

01-06-2011 | Original Article

Initial experiences with isolated limb perfusion for unresectable melanoma of the limb

Authors: L. Romics Jr., E. A. Dy, J. C. Coffey, D. Herlihy, F. Aftab, M. Z. Chaudhry, K. Fogarty, J. A. O’Donnell, H. P. Redmond

Published in: Irish Journal of Medical Science (1971 -) | Issue 2/2011

Abstract

Aims

Our initial results with isolated limb perfusion (ILP) using melphalan ± TNF alpha in patients with unresectable melanoma of the limb were analyzed.

Methods

15 ILPs were performed between 2001 and 2006. Indications for ILP were stage III or IV metastatic melanoma. Complete and partial response rates, time to local and systemic tumour progression rates, disease free and overall survival rates were retrospectively analyzed.

Results

Overall response rate was 93%, with a 67% complete response and a 26% partial response rate. In eight cases grade II, while in six cases grade III local toxicity was detected. However, one mortality was detected in the early postoperative phase due to a grade V complication. With a mean follow-up period of 2.7 years, eight patients had local progression and in four of those, systemic progression was detected.

Conclusions

ILP was generally well tolerated and limb salvage was achieved in all cases.

Grunhagen DJ, de Wilt JH, van Geel AN, Eggermont AM (2006) Isolated limb perfusion for melanoma patients—a review of its indications and the role of tumour necrosis factor-alpha. Eur J Surg Oncol (epub ahead of print)

Dong XD, Tyler D, Johnson JL et al (2000) Analysis of prognosis and disease progression after local recurrence of melanoma. Cancer 88:1063. doi:10.1002/(SICI)1097-0142(20000301)88:5<1063:AID-CNCR17>3.0.CO;2-E PubMedCrossRef

Creech O Jr, Krementz ET, Ryan RF, Winblad JN (1958) Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 148:616–632. doi:10.1097/00000658-195810000-00009 PubMedCrossRef

Eggermont AM (1996) Treatment of melanoma in-transit metastases confined to the limb. Cancer Surv 26:335–349PubMed

Grunhagen DJ, Brunstein F, Graveland WJ, van Geel AN, de Wilt JHW, Eggermont AMM (2004) One hundred consecutive isolated limb perfusions with TNF alpha and melphalan in melanoma patients with multiple in-transit metastases. Ann Surg 240:939–948. doi:10.1097/01.sla.0000146147.89667.ed PubMedCrossRef

Klaase JM, Kroon BBR, Eggermont AMM et al (1995) A retrospective comparative study evaluating the results of “mild” hyperthermic versus “controlled” normothermic perfusion for recurrent melanoma of the extremities. Eur J Cancer 31:73–81. doi:10.1016/0959-8049(94)00372-C CrossRef

Wieberdink J, Benckhuysen C, Braat RP et al (1982) Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 18:905–910. doi:10.1016/0277-5379(82)90235-8 PubMedCrossRef

WHO (1979) WHO Handbook for Reporting Results of Cancer Treatment. World Health Organisation, Geneva

Lienard D, Eggermont AM, Koops HS et al (1999) Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. Melanoma Res 9(5):491–502PubMedCrossRef

10.

Lienard D, Lejeune FJ, Ewalenko P (1992) In transit metastases of malignant melanoma treated by high dose rTNF alpha in combination with interferon gamma and melphalan in isolation perfusion. World J Surg 16:234–240. doi:10.1007/BF02071526 PubMedCrossRef

11.

Lienard D, Ewalenko P, Delmotte J-J, Renard N, Lejeune FJ (1992) High-dose recombinant tumour necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 10:52–60PubMed

12.

Noorda EM, Vrouenraets BC, Nieweg OE, van Geel AN, Eggermont AM, Kroon BB (2006) Repeat isolated limb perfusion with TNF alpha and melphalan for recurrent limb melanoma after failure of previous perfusion. Eur J Surg Oncol 32(3):318–324. doi:10.1016/j.ejso.2005.10.009 PubMedCrossRef

13.

Rossi CR, Foletto M, Mocellin S, Pilati P, Lise M (2004) Hyperthermic isolated limb perfusion with low-dose tumor necrosis factor alpha and melphalan for bulky in-transit melanoma metastases. Ann Surg Oncol 11(2):173–177. doi:10.1245/ASO.2004.03.019

14.

Vrouenraets BC, Nieweg OE, Kroon BBR (1996) Thirty-five years of isolated limb perfusion for melanoma: indications and results. Br J Surg 83:1319–1328. doi:10.1002/bjs.1800831004 PubMedCrossRef

15.

Bartlett DL, Ma G, Alexander HR, Libutti SK, Fraker DL (1997) Isolated limb reperfusion with TNF and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics. Cancer 80(11):2084–2090PubMedCrossRef

16.

Zogakis TG, Bartlett DL, Libutti SK et al (2001) Factors affecting survival after complete response to isolated limb perfusion in patients with in-transit melanoma. Ann Surg Oncol 8(10):771–778. doi:10.1007/s10434-001-0771-4 PubMedCrossRef

17.

Grunhagen DJ, de Wilt JH, Graveland WJ, Verhoef C, van Geel AN, Eggermont AM (2006) Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma. Cancer 106(8):1776–1784. doi:10.1002/cncr.21802 PubMedCrossRef

Title: Initial experiences with isolated limb perfusion for unresectable melanoma of the limb
Authors: L. Romics Jr.
E. A. Dy
J. C. Coffey
D. Herlihy
F. Aftab
M. Z. Chaudhry
K. Fogarty
J. A. O’Donnell
H. P. Redmond
Publication date: 01-06-2011
Publisher: Springer-Verlag
Published in: Irish Journal of Medical Science (1971 -) / Issue 2/2011
Print ISSN: 0021-1265
Electronic ISSN: 1863-4362
DOI: https://doi.org/10.1007/s11845-010-0664-2

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Aims

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2011

Profiling B-type natriuretic peptide in a stable heart failure population: a valuable adjunct to care

What has happened to people affected by thalidomide 50 years on?

Intra-abdominal drain fracture following pancreatic necrosectomy

Liaison neurologists facilitate accurate neurological diagnosis and management, resulting in substantial savings in the cost of inpatient care

Agreement between Framingham-DORICA and SCORE scales in estimation of cardiovascular risk in the patients suffering from metabolic syndrome in Granada (Spain)

Splenic mass with remote trauma history: a management dilemma

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials